ISPOR’s COMMITMENT TO GLOBAL INCLUSIVITY AND SCIENTIFIC EXCELLENCE

Published Mar 2, 2017
ANNOUNCEMENT

Princeton, NJ—March 2, 2017—“Science has no geographic boundaries,” said Nancy S. Berg, CEO and Executive Director of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR). “Scientific research and development is the basis for the rapid globalization of the ISPOR organization and its ongoing and strategic commitment to diverse stakeholder engagement. Scientific excellence and global inclusivity are key components of our organizational values, and of the global enterprise that our Society continues to reflect, encouraging and stimulating a culture of diverse scientific exchange.”

Berg posted these remarks following discussions on the impact of changing political landscapes, including possible travel restrictions as the Society prepares to host its major international meetings on health economics and outcomes research (HEOR) in countries in Asia, Europe, Latin America, and North America. As a scientific and educational society, ISPOR does not take positions on political issues; however, the Society strongly supports open scientific exchange within the global HEOR community, and views efforts to restrict such exchanges as impediments to its mission. ISPOR represents and serves a diverse global, multi-stakeholder audience of more than 20,000 individual and chapter members from 114 countries. The Society’s two MEDLINE®-indexed journals, Value in Health and Value in Health Regional Issues, publish studies from authors who span the globe. In addition, the members who serve in leadership roles for the Society, including the Board of Directors, editorial boards, conference chairs and committees, councils, roundtables, regional consortia and networks, chapters, task forces, and special interest groups represent perspectives from virtually every corner of the world. To foster this level of diversity and inclusion, ISPOR has established a number of initiatives that encourage and facilitate participation, including conference travel grants for attendees outside of North America and Western Europe, scientific awards that recognize researchers and authors worldwide, and membership fee waivers for individuals in low-income countries. It is through such initiatives and the ongoing support of its global network of consortia, networks, and chapters that ISPOR achieves its mission of promoting health economics and outcomes research excellence to improve decision making for health globally.

###

 

Related Stories

Promoting Fairness in Funding Decisions

Jun 24, 2026

Value in Health announced the publication of a special themed section of research papers that offer new tools to help health policy makers weigh fairness alongside cost-effectiveness when deciding which treatments and programs to fund.

Listening to Patients in the Real World

Jun 23, 2026

Value in Health, the official journal of ISPOR announced today the publication of an ISPOR Good Practices Report outlining 9 areas to strengthen the robustness, transparency, and feasibility of real-world patient-reported outcomes studies.

ISPOR Task Force Addresses Critical Gap in Surrogate Endpoint Guidance

May 28, 2026

Value in Health, announced the publication of an ISPOR Good Practices Report providing guidance on the use of surrogate endpoint evaluation methods in health technology assessment (HTA) decision making. The report, “Methods for Evaluation of Surrogate Endpoints for HTA Decision Making: A Good Practices Report of an ISPOR Task Force,” was published in the May 2026 issue of Value in Health.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×